Evaluation of the Predictive Value of the Microvesicle Coagulo-lytic Balance in the Recurrence of Venous Thrombosis (MICROREVE)
Venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE) affects about 1,200,000 individuals each year in Europe. About 50% of VTE are unprovoked and 20% of these patients will face a recurrent event after the usual three to six-month course of anticoagulant treatment. To date, most patients are given prolonged anticoagulant treatment. However, anticoagulant treatment are associated with a major risk of bleeding (3%/year). Thus an accurate identification of patients with unprovoked VTE with a low risk of recurrence is needed to avoid unnecessary anticoagulant treatment with a risk of bleeding.
Over the past few years, microparticles (MPs) which are small vesicles originating from the budding of cellular membranes have emerged as important biological entities regulating hemostasis. MPs expose at their surface procoagulant molecules such as phosphatidylserin and tissue factor (TF). All data obtained in mouse models support a role of MPs in venous thrombosis mediated by the TF activation. Moreover, results from clinical studies showed that TF-MPs was associated with the risk of venous thrombosis. However, the predictive value of TF-MPs in the recurrence of VTE is unknown. Besides, no study has taken into account the recent progresses in the understanding of the role of MPs in haemostasis. Indeed, MPs vectorize molecules which are not only procoagulant but also profibrinolytic. The net result depends on a balance between both activities (the coagulo-lytic balance). This balance is can be measured by two complimentary assays on MPs.
We hypothesized that the coagu-lytic balance of MPs is associated with an increased risk of VTE recurrence after stopping the anticoagulant treatment.
研究概览
研究类型
注册 (预期的)
联系人和位置
学习地点
-
-
-
Marseille、法国
- Assistance Publique Hopitaux de Marseille
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- adult patients with a VTE history with at least 3 months of anticoagulant treatment.
Exclusion Criteria:
-
学习计划
研究是如何设计的？
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
re-thrombosis
adult patients with a VTE history with at least 3 months of anticoagulant treatment, which suffered from a re-thrombosis within 5 years after stopping the anticoagulant treatment
|
Measuring microparticles (MPs) in Human Plasma Samples
|
|
no thrombosis recurrence
adult patients with a VTE history with at least 3 months of anticoagulant treatment, without thrombosis recurrence
|
Measuring microparticles (MPs) in Human Plasma Samples
|
研究衡量的是什么？
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
coagu-lytic balance of MPs
大体时间：12 months
|
12 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (预期的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.
静脉血栓栓塞症 (VTE)的临床试验
-
Alexion Pharmaceuticals, Inc.Portola Pharmaceuticals, LLC (a wholly owned subsidiary of Alexion Pharmaceuticals)终止
-
Janssen Research & Development, LLC完全的全膝关节置换手术后抗凝治疗预防 VTE比利时, 意大利, 马来西亚, 拉脱维亚, 西班牙, 火鸡, 保加利亚, 美国, 立陶宛, 俄罗斯联邦, 乌克兰, 日本, 阿根廷, 巴西, 加拿大, 波兰
-
Thomas Jefferson University招聘中
-
Infanta Leonor University HospitalFundación para la Investigación e Innovación Biomédica del Hospital Universitario Infanta...招聘中
-
McMaster UniversityCanadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network; International...尚未招聘
-
Regeneron Pharmaceuticals招聘中静脉血栓栓塞症 (VTE)美国, 日本, 立陶宛, 匈牙利, 拉脱维亚, 波兰, 保加利亚, 罗马尼亚
-
Ya-Wei XuFirst Affiliated Hospital, Sun Yat-Sen University; Nanfang Hospital of Southern Medical University招聘中